Ludipress
Ludipress is a direct tabletting excipient developed by BASF. It is a co-processed excipient composed of lactose monohydrate, polyvinylpyrrolidone, and crospovidone. Ludipress is designed to provide direct compression properties for the formulation of solid oral dosage forms.
Lab products found in correlation
5 protocols using ludipress
Development of Co-Processed Excipients
Masitinib Mesylate Tablet Formulation
Example 5
Preparation of Tablets by Direct Compression.
5.0 g Masitinib mesylate form M, 10.0 g Ludipress® ready to use tableting mixture (a low hygroscopicity/high flowability mixture of lactose monohydrate, povidine [Kollidon 30®] and crospovidone [Kollidon CL®] obtainable from BASF) and 0.2 g magnesiumstearate were sieved (0.8 mm sieve) and mixed for 5 min by using a Turbula mixer.
Tablets were compressed by using a Korsch XP1 tablet press and analyzed by XRPD. No conversion to crystal form I was detectable as evident from the lack of a peak at 11.2° 2-Theta.
Formulation Development and Characterization of FUR
Formulation Development and Evaluation
Effervescent Clotrimazole Tablets for Topical Use
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!